Spherix Incorporated (SPEX) news stock charts
Spherix Incorporated (SPEX) Investment Summary:
Spherix Incorporated (the “Company” or “Registrant”), a Delaware corporation, was founded in 1967. The Company’s principal segments have historically been InfoSpherix, our information services business, and BioSpherix, our biotechnology research and development business. On August 15, 2007, we sold our InfoSpherix business to devote our resources and attention to BioSpherix. In July 2007, we also launched Health Sciences, a technical and regulatory consulting business. The principal executive offices of the Company are located at 6430 Rockledge Drive, Suite 503, Bethesda, Maryland 20817, and its telephone number is (301) 897-2540. The Company’s Common Stock trades on the NASDAQ Global Market system under the symbol SPEX. Available Information Our principal Internet address is www.spherix.com. We make available free of charge on www.spherix. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f04%2f04%2f0001104659-08-022658.html#FIS_BUSINESS"SPHERIX INC (SPEX:NASDAQ)
Snapshot of SPHERIX INC (SPEX)
|
OPEN
$1.48
|
PREVIOUS CLOSE
$1.48
|
|
|
DAY HIGH
$1.51
|
DAY LOW
$1.37
|
|
|
52 WEEK HIGH
11/16/09 - $4.15
|
52 WEEK LOW
03/27/09 - $0.45
|
|
|
MARKET CAP
20.1M
|
AVERAGE VOLUME 10 D
157.1K
|
|
|
EPS TTM
$-0.45
|
SHARES OUTSTANDING
14.4M
|
|
|
SPEX Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for SPHERIX INC (SPEX)
Spherix Inc. announced the completion of patient enrollment in its global Phase 3 clinical trial NEET (70971-004), which is evaluating the safety and efficacy of D-tagatose as an oral treatment for Type 2 diabetes mellitus. The company expects the efficacy results to be available as soon as mid-year with the maintenance phase of the trial continuing through 2010. In December 2008, after the initiation of the Phase 3 clinical trial by Spherix, the FDA issued a Guidance for Industry which held that sponsors of diabetes drug trials should demonstrate that the therapy will not result in an unacceptable increase in cardiovascular risk. The FDA has further stated that the duration of the controlled phase in an efficacy trial is an important issue. In studies of recently approved products that lasted more than one year, sponsors have typically conducted a randomized, controlled study lasting at least six months, followed by an extension phase lasting six months or longer. In the protocol amendment submitted to the FDA last September, Spherix implemented the six-month randomized, controlled study followed by an extension phase lasting six months to establish the cardiovascular safety of D-tagatose in the treatment of Type 2 diabetes.
Spherix Inc. Presents at The 12th Annual BIO CEO & Investor Conference, Feb-08-2010 through Feb-09-2010. Venue: The Waldorf Astoria Hotel, 301 Park Ave., New York, NY 10022, United States.
Spherix Inc. Presents at OneMedForum 2010 Emerging Company Finance Conference, Jan-12-2010 through Jan-14-2010. Venue: Sir Francis Drake Hotel, 450 Powell Street Union Square, San Francisco, California, United States.
Spherix Incorporated financial resources
SPEX Competitors
| Company | Last | Change | |
| No competitor information is available for SPEX. | |||
| Market data is delayed at least 15 minutes. | |||
Industry Analysis
| Valuation | SPEX | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 14.6x |
|
| Price/Book | 4.3x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 12.8x |
|
|
SPEX |
||
SPEX transactions
| Type Date |
Target |
|
Private Placement
November 16, 2009 |
-- |
More Recent Financial News About Spherix Incorporated
Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco
Read article
Spherix Announces the Closing of $6.3 Million Registered Direct Offering
Read article
Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
Read article
Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
Read article
Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco
Read article
SPHERIX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Read article
UPDATE - Spherix says diabetes drug shows promise; shares jump
Read article
Spherix Incorporated To Raise $6.3 Million In Registered Direct Offering
Read article
SPHERIX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Read article
Spherix Announces the Closing of $6.3 Million Registered Direct Offering
Read article